NEW YORK (GenomeWeb) – Janssen Diagnostics is now offering next-generation sequencing cancer panels from Asuragen to its research customers, expanding its services in rare cell detection, the company said today.

Under an agreement with Asuragen, Janssen is offering its customers Asuragen's proprietary SuraSeq panels. Asuragen launched two SuraSeq panels last year, which cover hotspot mutations in up to 17 oncogenes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.